28PD - Measuring the population impact of introducing stereotactic ablative radiotherapy (SABR) for stage I NSCLC in Canada

Date 28 March 2014
Event ELCC 2014
Session Poster Discussion 2
Topics Non-Small-Cell Lung Cancer, Early Stage
Surgery and/or Radiotherapy of Cancer
Presenter Alexander Louie
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A.V. Louie1, G.B. Rodrigues2, D.A. Palma2, S. Senan3
  • 1Radiation Oncology, VU University Medical Center, 1007 MB - Amsterdam/NL
  • 2Radiation Oncology, London Regional Cancer Program, London/CA
  • 3Radiation Oncology, VU University Medical Center, Amsterdam/NL

Abstract

SABR achieves long-term local control rates of up to 90% in stage I NSCLC. We used the Cancer Risk Management Model (CRMM) to estimate the health and economic impact of introducing SABR for stage I NSCLC in Canada.